EAM Investors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

EAM Investors’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,156	Closed	-$785K	–	365
2022 Q2	$785K	Sell	4,156 -67	-2%	-$13.5K	0.19%	231
2022 Q1	$1.05M	Buy	+4,223	New	+$667K	0.2%	250

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

EAM Investors's EIGR Position: Q3 2022 in Review

EAM Investors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2022, closing a stake of 4,156 shares — an estimated $785K sold.

EAM Investors first reported a position in EIGR in Q1 2022 and held it in 2 quarters. The position peaked at $1.05M in Q1 2022. 92 funds tracked by Wall St. Rank hold EIGR as of Q3 2022.

EAM Investors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
EAM Investors sold 4,156 Eiger BioPharmaceuticals, Inc. shares in Q3 2022, an estimated $785K.
EAM Investors first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2022 and held it in 2 quarters.
EAM Investors's Eiger BioPharmaceuticals, Inc. position peaked at $1.05M in Q1 2022.
92 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2022.

Based on EAM Investors's 13F filing for Q3 2022, filed 14 Nov 2022.